M Pharmaceutical Inc. (CSE:MQ) announced today that is has entered into an agreement with Chinese manufacturer Rishena Co. Ltd. to produce their Trimtec gastric functional neuro-stimulation device.

M Pharmaceutical Inc. (CSE:MQ) announced today that is has entered into an agreement with Chinese manufacturer Rishena Co. Ltd. to produce their Trimtec gastric functional neuro-stimulation device.
As quoted in the press release:

M Pharmaceutical Inc. has entered into a manufacturing supply agreement with Rishena Co. Ltd. of Changzhou, China, to manufacture the company’s Trimtec gastric functional neuro-stimulation device. Under the terms of the agreement, Rishena will be the exclusive supplier of laparoscopically-implantable Trimtec devices to M Pharmaceutical for the North and South American markets. The devices will be fully programmable and rechargeable through an abdominal belt. Rishena commits, at its expense, to obtain ISO 13485 certification(1) for Trimtec manufacturing prior to the Company’s commercial launch of Trimtec.

M Pharmaceutical President and CEO of M Pharma Dr. Martin Mintchev is quoted as saying:

Our agreement with Rishena is an important step forward in the development of Trimtec for the North and South American markets, we are delighted to collaborate with an experienced and respected medical device manufacturer such as Rishena and look forward to successful collaboration with them.

Click here for the full M Pharmaceutical Inc. (CSE:MQ) press release.
Click here for the M Pharmaceutical Inc. (CSE:MQ) profile.